India Immunotherapy for Leukemia Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Immunotherapy for Leukemia Market was valued at USD 458.0 million in 2025 and is projected to reach USD 721.13 million by 2032, growing at a CAGR of approximately 6.7% during 2026–2032.
India Immunotherapy for Leukemia Market Highlights
| Report Metric | Details |
| Report Name | India Immunotherapy for Leukemia Market |
| Market Size 2025 | USD 458.0 million |
| Market Size 2032 | USD 721.13 million |
| Absolute Growth 2025–2032 | USD 263.13 million |
| CAGR 2026–2032 | 6.7% |
| Peak Annual Growth | 8.6% in 2032 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Immunotherapy Type, 2025 | Monoclonal Antibodies (52% share) |
| Leading Leukemia Subtype, 2025 | ALL (39% share) |
| Leading Delivery Method, 2025 | Intravenous Infusion (40% share) |
| Leading End User, 2025 | Cancer Treatment Centers (46% share) |
| Fastest-Growing Immunotherapy Type | CAR-T Cell Therapy (9.0% CAGR) |
| Fastest-Growing Leukemia Subtype | AML (8.2% CAGR) |
| Fastest-Growing End User | Immunotherapy Clinics (8.4% CAGR) |
| Growing Sector | Cancer Treatment Centers |
| Key End Users | Cancer Treatment Centers, Hematology Departments, Immunotherapy Clinics |
India Immunotherapy for Leukemia Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The following table presents the estimated annual growth rate for each year together with the principal factor influencing market performance.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 6.8 | The market experienced strong demand due to increased leukemia cases and advancements in treatment protocols. |
| 2023 | 4.6 | Growth slowed as healthcare infrastructure challenges persisted despite ongoing treatment developments. |
| 2024 | 5.0 | Demand picked up as more healthcare providers adopted immunotherapy protocols, particularly in urban areas. |
| 2025 | 4.5 | The market grew slower as competition increased among available treatment options, impacting patient choices. |
| 2026 | 4.7 | Growth accelerated as CAR-T cell therapy gained wider acceptance among healthcare facilities, improving patient outcomes. |
| 2027 | 4.2 | A slowdown occurred as the market adjusted to new treatment guidelines and protocols introduced by the National Medical Commission. |
| 2028 | 7.6 | Demand surged with the expansion of immunotherapy clinics across urban areas, enhancing patient access to treatments. |
| 2029 | 8.4 | Growth continued to rise as awareness of treatment options increased among patients, driven by national health initiatives. |
| 2030 | 6.5 | A slowdown was noted as the market faced regulatory challenges affecting approvals and treatment accessibility. |
| 2031 | 7.0 | Growth picked up again as new therapies entered the market and expanded treatment options for leukemia patients. |
| 2032 | 8.6 | The market peaked with advancements in CAR-T cell therapy and improved access for patients through new healthcare initiatives. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Immunotherapy for Leukemia Market Synopsis
The Immunotherapy for Leukemia Market in India encompasses advanced treatments that harness the immune system to combat leukemia. Techniques like CAR-T cell therapy and monoclonal antibodies are developed through complex biological processes. Growth in this market stems from the rising incidence of leukemia and increased investment in healthcare infrastructure. With over 1 million new cancer cases annually, the demand for effective therapies is substantial. The National Cancer Control Programme and ongoing research initiatives are propelling this growth, ensuring better access to treatment for patients.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Increasing incidence of leukemia in urban areas drives demand for innovative treatments. | Driver | High | ALL |
| Expansion of immunotherapy clinics enhances patient access to advanced therapies. | Driver | High | Cancer Treatment Centers |
| Rising investment in CAR-T cell therapy research creates opportunities for new entrants. | Opportunity | High | CAR-T Cell Therapy |
| Growing awareness among patients about immunotherapy options opens new market segments. | Opportunity | High | Immunotherapy Clinics |
| High cost of CAR-T therapy limits accessibility for many patients. | Restraint | High | CAR-T Cell Therapy |
| Healthcare infrastructure challenges hinder the delivery of immunotherapy treatments. | Restraint | Medium | Cancer Treatment Centers |
| The Immunotherapy for Leukemia market in India faces regulatory hurdles that delay approvals. | Challenge | High | ALL |
| Limited availability of trained professionals affects the adoption of immunotherapy. | Challenge | Medium | Hematology Departments |
Evaluation of Drivers in India Immunotherapy for Leukemia Market (2026–2032)
Key forces behind demand, with the segment each one moves most, are listed below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Rising leukemia incidence drives demand for immunotherapy treatments. | ALL | India has over 1 million new cancer cases annually, increasing the need for effective therapies. |
| Investment in CAR-T cell therapy research boosts treatment options. | CAR-T Cell Therapy | The Department of Biotechnology launched a programme in 2023 to improve CAR-T therapy access. |
| Expansion of cancer treatment centers increases patient access to immunotherapy. | Cancer Treatment Centers | Hematology departments in major cities like Mumbai and Delhi are expanding their services. |
| Growing patient awareness about immunotherapy options boosts market demand. | Immunotherapy Clinics | The National Health Mission promotes awareness and access to cancer treatments. |
| Support from the Indian Council of Medical Research promotes research initiatives. | Monoclonal Antibodies | The council actively supports immunotherapy research initiatives across the country. |
The Immunotherapy for Leukemia market in India is growing on the back of rising leukemia incidence, expanding healthcare infrastructure, and increased investment in research. Over 1 million new cancer cases annually create a demand for effective treatments. As hematology departments in urban areas expand their services, patient access to advanced therapies improves, resulting in higher demand for treatments.
Evaluation of Restraints in India Immunotherapy for Leukemia Market
The main factors holding the market back are set out below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| High cost of CAR-T therapy limits patient access. | CAR-T Cell Therapy | The average cost of CAR-T therapy in India is approximately INR 30 lakhs per patient. |
| Healthcare infrastructure challenges hinder treatment delivery. | Cancer Treatment Centers | Limited facilities and resources affect the availability of immunotherapy treatments, particularly in rural areas. |
| Regulatory hurdles delay the approval of new therapies. | ALL | The Drug Controller General of India regulates immunotherapy approvals, causing delays in bringing new treatments to market. |
| Limited availability of trained professionals affects treatment adoption. | Hematology Departments | A shortage of specialists in immunotherapy restricts patient access to advanced treatments, impacting outcomes. |
| Competition among treatment options increases market complexity. | Immunotherapy Clinics | As more therapies enter the market, patients face challenges in choosing the right option, complicating decision-making. |
India Immunotherapy for Leukemia Market Challenges
The India immunotherapy for leukemia market faces a supply issue due to limited production capacity for CAR-T cell therapies, which delays treatment for over 1 million new cancer patients annually. This situation arises because advanced manufacturing processes require substantial investment and expertise, leading to longer wait times for hospitals and higher costs for patients, with CAR-T therapy averaging INR 30 lakhs. Technological challenges persist as the complexity of genetic engineering slows the introduction of new therapies in clinics, limiting patient access to crucial treatments. A lack of skilled healthcare professionals further complicates the situation, making it difficult for hospitals to recruit trained staff, which adversely affects patient outcomes and satisfaction.
Trends in the India Immunotherapy for Leukemia Market
Four trends stand out in the India Immunotherapy for Leukemia Market.
- Shift Towards CAR-T Cell Therapy: In 2023, CAR-T cell therapy gained traction as a preferred treatment for leukemia, with a projected CAGR of 9.0% through 2032. This shift reflects increased investment in research and development, improving patient outcomes.
- Growing Number of Immunotherapy Clinics: Since 2022, the number of dedicated immunotherapy clinics has increased, driven by rising patient demand. This growth is evident in urban areas where access to advanced treatments is expanding, enhancing patient care.
- Increased Patient Awareness: Since 2021, patient awareness campaigns have improved understanding of immunotherapy options. This trend is reflected in the rising number of patients seeking treatments at cancer centres, leading to higher treatment uptake.
- Expansion of Treatment Protocols: In 2023, updated guidelines from the National Medical Commission included immunotherapy protocols, improving treatment standards. This change is expected to enhance therapy adoption and patient outcomes across the healthcare system.
Investment Opportunities in the India Immunotherapy for Leukemia Market
Some of the investment opportunities in the India Immunotherapy for Leukemia Market are mentioned below.
- Investment in CAR-T Cell Therapy: With the average cost of CAR-T therapy at INR 30 lakhs, there is a gap in affordable treatment options. Investing in research and development can attract healthcare providers seeking solutions to improve access.
- Expansion of Immunotherapy Clinics: The ongoing increase in leukemia cases creates a demand for more immunotherapy clinics. Partnering with local healthcare providers can facilitate entry into this growing market segment, enhancing patient access to treatments.
- Development of Cost-Effective Therapies: The high cost of existing therapies presents an opportunity for developing more affordable options. Targeting cancer treatment centres can help reach a broader patient base, improving overall treatment access.
- Collaboration with Research Institutions: Collaborating with institutions focused on immunotherapy research can enhance treatment offerings. The Indian Council of Medical Research is a key player in this space, providing funding opportunities to support innovative projects.
Government Initiatives in the India Immunotherapy for Leukemia Market
In 2021, the Ministry of Health and Family Welfare launched the National Cancer Control Programme to improve access to cancer treatments, including immunotherapy. This initiative aims to increase the availability of advanced therapies across the country, addressing the growing incidence of leukemia. Additionally, the National Medical Commission updated guidelines in 2023 to include immunotherapy protocols, ensuring that healthcare providers adhere to the latest standards in treatment delivery and improving patient outcomes.
In 2022, the Department of Biotechnology initiated the 'Biotechnology Industry Research Assistance Council' scheme, which allocates funding to support immunotherapy research initiatives. This programme aims to promote innovation and development in the field of immunotherapy, benefiting both producers and patients. The Indian Council of Medical Research also plays a significant role in promoting research and development, ensuring that new therapies are effectively integrated into clinical practice, with funding exceeding INR 100 crores for various projects.
Future Insight of the India Immunotherapy for Leukemia Market
Growth in the India immunotherapy for leukemia market is anticipated over the next several years, driven by key developments. By 2032, increased funding for research initiatives will likely produce more advanced therapies, broadening treatment options for patients. The launch of programmes to improve access to CAR-T cell therapy will enhance availability, benefiting healthcare providers and patients. Additionally, the ongoing expansion of hematology services in urban centres will streamline care delivery, ensuring timely and effective treatment for those affected by leukemia.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Immunotherapy Type – Monoclonal Antibodies Dominated, CAR-T Cell Therapy Expected to Grow Fastest
According to Sachin Kumar Rai, Senior Research Analyst at 6Wresearch, the largest immunotherapy type category in 2025 was Monoclonal Antibodies, with a 52% share of total revenue. Monoclonal antibodies hold the largest market share due to their proven effectiveness in targeting specific antigens on leukemia cells. Their integration into treatment protocols across various healthcare settings in India reinforces their preferred status among medical professionals. Over 2026–2032, CAR-T Cell Therapy is expected to post the fastest growth, at a CAGR of 9.0%. CAR-T cell therapy is rapidly gaining traction as it provides a targeted method to eradicate leukemia cells, with approvals increasing since 2020. The recent initiative to improve CAR-T therapy access by the government will further accelerate its adoption in the market. Suppliers should prioritise the expansion of CAR-T cell therapy offerings to align with the growing demand in the Indian immunotherapy market.
By Leukemia Subtype – ALL Dominated, AML Expected to Grow Fastest
In 2025, ALL led the leukemia subtype split with a 39% share. Acute Lymphoblastic Leukemia (ALL) holds the largest market share due to its significant treatment focus within immunotherapy protocols, reflecting the high incidence rates of this subtype in India. The prioritisation of ALL in clinical guidelines and treatment strategies further solidifies its leading position. AML is set to record the highest CAGR in this split, 8.2% over 2026–2032. Acute Myeloid Leukemia (AML) is witnessing the fastest growth in immunotherapy applications, driven by an increase in dedicated research and ongoing clinical trials targeting this specific subtype. The rising incidence of AML in urban populations is expected to accelerate its adoption in treatment. Buyers should consider investing in AML-targeted therapies, as the market for these treatments is set to expand rapidly.
By Delivery Method – Intravenous Infusion Dominated and Is Expected to Record the Fastest Growth
Intravenous Infusion accounted for a 40% market share by delivery method in 2025. Intravenous infusion commands the largest market share as it is the primary method for administering many immunotherapies, ensuring effective delivery to patients. Its established protocols in treatment facilities across India contribute to its widespread acceptance and use. Intravenous Infusion is also forecast to expand faster than any other category, at a CAGR of 7.9% over 2026–2032. Intravenous infusion not only leads the market but also shows rapid growth due to its effectiveness in delivering advanced therapies like CAR-T cell treatments. As these therapies gain traction, the demand for intravenous delivery methods is expected to increase significantly. Suppliers must enhance their intravenous infusion systems to meet the rising demand for immunotherapy treatments.
By End User – Cancer Treatment Centers Dominated, Immunotherapy Clinics Expected to Grow Fastest
Cancer Treatment Centers took a 46% share of end user in 2025, more than any other category. Cancer treatment centers dominate the market share as they are the main facilities providing immunotherapy, equipped with the necessary resources and expertise for effective patient care. Their comprehensive approach to cancer treatment solidifies their leading position in the market. Immunotherapy Clinics are projected to grow fastest, at a CAGR of 8.4% during 2026–2032. Immunotherapy clinics are expanding at the fastest rate, reflecting a shift towards specialised facilities that focus exclusively on immunotherapy. This trend is driven by the increasing patient demand for tailored cancer treatment options. Suppliers should target immunotherapy clinics to leverage the growing preference for specialised cancer treatment facilities.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Immunotherapy for Leukemia Market Outlook
- Market Size of India Immunotherapy for Leukemia Market, 2025
- Forecast of India Immunotherapy for Leukemia Market, 2032
- Historical Data and Forecast of India Immunotherapy for Leukemia Revenues & Volume for the Period 2022 - 2032F
- India Immunotherapy for Leukemia Market Trend Evolution
- India Immunotherapy for Leukemia Market Drivers and Challenges
- India Immunotherapy for Leukemia Price Trends
- India Immunotherapy for Leukemia Porter's Five Forces
- India Immunotherapy for Leukemia Industry Life Cycle
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Immunotherapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By CAR-T Cell Therapy for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Immune Checkpoint Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Tumor Vaccines for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Monoclonal Antibodies for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Leukemia Subtype for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By ALL, CLL for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By AML for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Chronic Leukemia for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By CD20, CD52 Targets for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Delivery Method for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Intravenous Infusion for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Systemic Injection for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Subcutaneous for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By IV for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Cancer Treatment Centers for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Hematology Departments for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Immunotherapy Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Immunotherapy for Leukemia Market Revenues & Volume By Clinical Oncology Labs for the Period 2022 - 2032F
- India Immunotherapy for Leukemia Import Export Trade Statistics
- Market Opportunity Assessment By Immunotherapy Type
- Market Opportunity Assessment By Leukemia Subtype
- Market Opportunity Assessment By Delivery Method
- Market Opportunity Assessment By End User
- India Immunotherapy for Leukemia Top Companies Market Share
- India Immunotherapy for Leukemia Competitive Benchmarking By Technical and Operational Parameters
- India Immunotherapy for Leukemia Company Profiles
- India Immunotherapy for Leukemia Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Immunotherapy Type
- CAR-T Cell Therapy
- Immune Checkpoint Inhibitors
- Tumor Vaccines
- Monoclonal Antibodies
By Leukemia Subtype
- ALL
- CLL
- AML
- Chronic Leukemia
- CD20
- CD52 Targets
By Delivery Method
- Intravenous Infusion
- Systemic Injection
- Subcutaneous
- IV
By End User
- Cancer Treatment Centers
- Hematology Departments
- Immunotherapy Clinics
- Clinical Oncology Labs
